Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941
Top Cited Papers
- 1 May 2009
- journal article
- research article
- Published by Elsevier in Cancer Cell
- Vol. 15 (5) , 429-440
- https://doi.org/10.1016/j.ccr.2009.03.020
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235Cancer Research, 2008
- The Identification of 2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of CancerJournal of Medicinal Chemistry, 2008
- The selectivity of protein kinase inhibitors: a further updateBiochemical Journal, 2007
- A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast CancerCancer Cell, 2007
- Endocytosis and Sorting of ErbB2 and the Site of Action of Cancer Therapeutics Trastuzumab and GeldanamycinMolecular Biology of the Cell, 2004
- Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growthCancer Cell, 2002
- Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targetsNature Medicine, 2000
- Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic DiseaseJournal of Clinical Oncology, 1999
- The Relationship between Human Epidermal Growth-like Factor Receptor Expression and Cellular Transformation in NIH3T3 CellsJournal of Biological Chemistry, 1996
- Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitorsAdvances in Enzyme Regulation, 1984